Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We speculate that hsa_circRNA_104268/hsa-miR-214-3p/E2F2, hsa_circRNA_104168/hsa-miR-139-5p/HRAS, and hsa_circRNA_104769/hsa-miR-93-5p/JUN interaction pairs may play a vital role in HCC.
|
31222831 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pathway analysis suggested that putative target genes of these essential miRNAs were involved in HCC-associated signaling pathways, such as Wnt, TGF-β, and Ras; whereas protein-protein network (PPI) analysis demonstrated that some validated target genes of these miRNAs, such as PIK3CA, AKT1, MYC, JUN, SMAD4, and SRC, were hub target genes as they have more counts of interacting protein.
|
31293639 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our analysis disclosed the immune subversion was the major signature of HCC associated closely with JUN, VEGFA, TNFSF10, and TLR4, which could be novel noninvasive biomarkers in peripheral blood and targets for early diagnosis and therapy of HCC.
|
31531018 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Liver-enriched activator protein 1 as an isoform of CCAAT/enhancer-binding protein beta suppresses stem cell features of hepatocellular carcinoma.
|
29731667 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Modulating c-Jun may be useful for certain HCC patients with sorafenib resistance.
|
28323861 |
2017 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This information sheds light on the possible role of lncRNA-UCA1 and C-JUN mRNA as promising diagnostic and prognostic markers as well as potential therapeutic targets in HCC.
|
27215316 |
2016 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma.
|
25230788 |
2015 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells.
|
25526895 |
2015 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among them, one novel SNP was found in activator protein-1 (AP2), a transcription factor binding site (-483 A to C) that may be associated with the susceptibility to HCC (P = 0.012) but no associations were found for other observed variations.This mutation could be tumor-specific.
|
24659263 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Auto-activation of c-JUN gene by amino acid deprivation of hepatocellular carcinoma cells reveals a novel c-JUN-mediated signaling pathway.
|
21862593 |
2011 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the expression of KITENIN and AP-1 target genes at mRNA levels by RT-PCR in human HCC tissues and paired normal hepatic mucosa of the same patients taken by surgery.
|
21473287 |
2011 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice.
|
20214788 |
2010 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To determine whether JUN (the oncogene encoding c-Jun protein) is amplified and overexpressed in hepatocellular carcinoma (HCC).
|
20044606 |
2009 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results reveal a new AP-1 site within the TRAIL promoter functionally involved in TGF-beta-induced TRAIL expression and apoptosis in hepatomas and thus provide evidence for the underlying mechanism by which TGF-beta might regulate cell death in liver cancer.
|
18644981 |
2008 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Transforming growth factor-beta-mediated tumor necrosis factor-related apoptosis-inducing ligand expression and apoptosis in hepatoma cells requires functional cooperation between Smad proteins and activator protein-1.
|
18644981 |
2008 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our findings demonstrated for the first time that acetaldehyde activated NF-kappaB and AP-1 activities via IkappaB, JNK/beta-TrCP, and p38 signaling pathways, resulting in MMP-9 gene expression and hepatocarcinoma cells invasion.
|
17543481 |
2007 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, whereas wild-type TRs interfere with c-Jun/AP-1 function in a T3-dependent fashion and suppress anchorage-independent growth when ectopically expressed in HepG2 cells, at least certain of the HCC mutants did not exert these inhibitory properties.
|
16434963 |
2006 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To study the role of c-Jun N-terminal kinase (JNK) and its relation to transcription factor AP-1 and Jun family proteins in hepatocellular carcinoma (HCC) with or without hepatitis B virus (HBV) infection.
|
15927205 |
2005 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Activation of transcription factors NF-kappaB and AP-1 and their relations with apoptosis associated-proteins in hepatocellular carcinoma.
|
15991283 |
2005 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies showed that c-Jun protein plays a positive role in cell proliferation of normal hepatocytes and was detected in hepatocellular carcinoma (HCC) tissues.
|
12168099 |
2002 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The possibility that the hbx protein may activate certain protooncogenes was investigated and we found that hbx can activate the protooncogene c-jun promoter. c-Jun was found to be expressed at a very low level in normal liver tissue but at high levels in HCCs of HBV-infected patients.
|
8390762 |
1993 |